1. Kane JM, Leucht S, Carpenter D, et al. Expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64(suppl 12):1-100.
2. Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005;79:145-55.
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
4. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior antipsychotic treatment. Am J Psychiatry 2006;163:600-10.
5. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-22.
6. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006;163:2080-9.
7. Jones PB, Barnes T, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS). Arch Gen Psychiatry 2006;63:1079-87.
8. Lewis SW, Barnes TRE, Davies L, et al. Randomised controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32:715-23.
9. Nasrallah HA. CATIE’s surprises: in antipsychotics’ square-off, were there winners or losers? Current Psychiatry 2006;5(2):49-65.
10. Buckley PF. Which antipsychotic do I choose next? CATIE phase 2 offers insights on efficacy and tolerability. Current Psychiatry 2006;5(9):27-43.
11. Tandon R, Constantine R. Avoiding EPS is key to realizing ‘atypical’ benefits. Current Psychiatry 2006;5(11):35-45.
12. Lewis SW, Davies L, Jones PB, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technology Assessment 2006;10(#17):1-182.Available at http://www.hta.ac.uk/project/1078.asp. Accessed January 3, 2007.
13. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for assessing the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-98.
14. Tandon R, Davis JM, Carpenter WT. CATIE, CUtLASS, and the FGA-SGA debate (letter). Arch Gen Psychiatry 2007 (in press).
15. Lieberman J. Comparative effectiveness of antipsychotic drugs: a commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study and Clinical Antipsychotic Trials of Intervention Effectiveness. Arch Gen Psychiatry 2006;63:1069-72.
16. Rosenheck RA. Outcomes, costs, and policy caution: a commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study. Arch Gen Psychiatry 2006;63:1074-6.
17. Tandon R. Comparative effectiveness of antipsychotics in the treatment of schizophrenia: what CATIE tells us—Parts 1 and 2. International Drug Therapy Newsletter 2006;41(7,9):51-8,67-74.
18. Meltzer HY, Bobo WV. Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS Spectrums 2006;11(suppl 7):14-24.
19. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 2006;67(suppl 5):9-14.
20. Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res 2006;79:231-8.
21. Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006;163:2090-5.
22. Davis JM, Marder S, Tamminga CA. Switch or stay? Am J Psychiatry 2006;163:2032-3.
23. Tandon R, Targum SD, Nasrallah HA, et al. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. Journal of Psychiatric Practice 2006;12:348-63.
